Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: Time to Call It Quits?

James W. Murrough; Dennis S. Charney

doi:10.1016/j.biopsych.2017.10.012

Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: Time to Call It Quits?

Research output: Contribution to journal › Comment/debate

12 Scopus citations

Original language	English
Pages (from-to)	858-860
Number of pages	3
Journal	Biological Psychiatry
Volume	82
Issue number	12
DOIs	https://doi.org/10.1016/j.biopsych.2017.10.012
State	Published - 15 Dec 2017

Access to Document

10.1016/j.biopsych.2017.10.012

Cite this

@article{481f95454843412cb30718a0cece15ee,

title = "Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: Time to Call It Quits?",

author = "Murrough, {James W.} and Charney, {Dennis S.}",

note = "Funding Information: In the past 3 years, JWM has provided consultation services for Allergan, Fortress Biotech, Inc., Novartis, Janssen Research and Development, Genentech, and ProPhase and has received research support from Avanir Pharmaceuticals, Inc. JWM and DSC are named on a patent pending for neuropeptide Y as a treatment for mood and anxiety disorders as well as on patents pending for lithium to extend the antidepressant effect of ketamine and ketamine plus lithium as a treatment for suicidal ideation. DSC, the Dean of Icahn School of Medicine at Mount Sinai, and Icahn School of Medicine at Mount Sinai have been named on a use patent on ketamine for the treatment of depression. DSC and the Icahn School of Medicine at Mount Sinai could potentially benefit if ketamine were to gain approval for the treatment of depression. The authors report no other biomedical financial interests or potential conflicts of interest. ",

year = "2017",

month = dec,

day = "15",

doi = "10.1016/j.biopsych.2017.10.012",

language = "English",

volume = "82",

pages = "858--860",

journal = "Biological Psychiatry",

issn = "0006-3223",

publisher = "Elsevier USA",

number = "12",

}

TY - JOUR

T1 - Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders

T2 - Time to Call It Quits?

AU - Murrough, James W.

AU - Charney, Dennis S.

N1 - Funding Information: In the past 3 years, JWM has provided consultation services for Allergan, Fortress Biotech, Inc., Novartis, Janssen Research and Development, Genentech, and ProPhase and has received research support from Avanir Pharmaceuticals, Inc. JWM and DSC are named on a patent pending for neuropeptide Y as a treatment for mood and anxiety disorders as well as on patents pending for lithium to extend the antidepressant effect of ketamine and ketamine plus lithium as a treatment for suicidal ideation. DSC, the Dean of Icahn School of Medicine at Mount Sinai, and Icahn School of Medicine at Mount Sinai have been named on a use patent on ketamine for the treatment of depression. DSC and the Icahn School of Medicine at Mount Sinai could potentially benefit if ketamine were to gain approval for the treatment of depression. The authors report no other biomedical financial interests or potential conflicts of interest.

PY - 2017/12/15

Y1 - 2017/12/15

UR - http://www.scopus.com/inward/record.url?scp=85033708717&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2017.10.012

DO - 10.1016/j.biopsych.2017.10.012

M3 - Comment/debate

C2 - 29129198

AN - SCOPUS:85033708717

SN - 0006-3223

VL - 82

SP - 858

EP - 860

JO - Biological Psychiatry

JF - Biological Psychiatry

IS - 12

ER -